The fifth round of centralized drug procurement, 79 varieties or selected (list attached)

According to the
fifth round of national procurement, a batch of varieties that meet the conditions
.
The latest data of the Minet.
com shows that as of March 15, 482 varieties have been approved or deemed to have passed the consistency evaluation by enterprises , of which 189 varieties ( 155 generic name drugs) have been included in the national centralized procurement
.
Among the remaining 293 varieties (285 generic drugs), 110 generic drugs have over-rated companies with 2 or more, of which 79 generic drugs meet the national centralized procurement requirements, that is, the number of over-rated companies has reached 3 1 or above or 1 original research + 2 or above reviewed enterprises
.
According to data from Meinenet, the total sales of 79 generic drugs in China's public medical institutions in 2019 exceeded 100 billion yuan, of which 63 drugs sold more than 100 million yuan, and 33 drugs sold more than 1 billion yuan.
It is worth noting that, The sales of ceftazidime injection and budesonide suspension for inhalation directly exceeded 6 billion yuan
.
According to Cyber ​​Blue, the 79 varieties that meet the requirements of national procurement so far involve a number of multinational pharmaceutical companies-including Bayer, AstraZeneca, Takeda, GlaxoSmithKline, Xinji, Roche, Sanofi, Li Lai, Daiichi Sankyo, Boehringer Ingelheim, Pfizer, Novartis, General Electric, Braun, Otsuka Pharmaceutical, Gilead, Xi'an Janssen, Merck, Fresenius Kabi, Squibb, Tanabe Mitsubishi Pharmaceuticals, Saisheng Waiting for more than 20 houses
.

Many varieties of original research occupy the main market.

Specifically, AstraZeneca, Pfizer, Merck, Sanofi, GlaxoSmithKline, Novartis, Boehringer Ingelheim, Roche and several foreign companies involve more varieties
.
AstraZeneca’s original drugs include: esomeprazole injection, isosorbide sustained-release and controlled-release dosage form, bicalutamide oral regular-release dosage form, ropivacaine injection, saxagliptin oral regular-release dosage form, and US Torolol oral normal-release dosage form, budesonide suspension for inhalation 7
.
The original research drugs involved in Pfizer are: Azithromycin Injection, Fluconazole Sodium Chloride Injection, Glipizide Oral Constant Release Formulation, Misoprostol Oral Normal Release Formulation, Venlafaxine Controlled Release Formulation, Glipizide There are 9 sustained-release controlled-release dosage forms, linezolid glucose injection, sunitinib oral regular-release dosage forms, and nitroglycerin oral regular-release dosage forms
.
In addition, Sanofi involved three original research drugs-docetaxel injection, oxaliplatin injection, and amiodarone oral regular-release dosage form; Roche involved two original research drugs-ceftriaxone injection, mycophenolate mofetil Oral regular-release dosage form of ester; Merck involves 3 original research drugs-Losartan hydrochlorothiazide oral regular-release dosage form, sitagliptin oral regular-release dosage form, and sitagliptin oral regular-release dosage form; GlaxoSmithKline involves 3 original researches Medicines-lamivudine oral regular-release dosage form, cefuroxime injection, ceftazidime injection
.

　　Among them, the original research drug companies occupy 100% of the market share:
Rivaroxaban oral regular-release dosage form, Bayer's market share is 100%, Alogliptin oral regular-release dosage form, Takeda's market share is 100%, and Afatinib oral regular-release dosage form Dosage form, Boehringer Ingelheim market share 100%, Bendamustine injection, Cehalon market share 100%, Olmesartan medoxomil hydrochlorothiazide oral normal-release dosage form, Daiichi Sankyo's market share 100%, Profol tenofovir oral Regular-release dosage form, Gilead’s market share is 100%, dabigatran etexilate oral regular-release dosage form, Boehringer Ingelheim’s market share is 100%, dutasteride oral regular-release dosage form, GlaxoSmithKline’s market share is 100%, Suny Tinib, Pfizer’s market share of 100%, sitagliptin oral regular-release dosage form of metformin, Merck’s market share 100%, sitagliptin oral regular-release dosage form, Merck’s market share 100%, budesonide suspension for inhalation, Salicom’s market share is 100%, ipratropium bromide solution for inhalation, Boehringer Ingelheim’s market share is 100%, moxifloxacin eye drops, Novartis’s market share is 100%.
.
.
Review the fourth batch of national sources, according to Mi Nei.
com According to the data, among the 45 products of the fourth batch of national procurement, 21 drugs have original research manufacturers-11 of them have original research manufacturers in the market share of China's public medical institutions in the terminal competition pattern in 2019.

.
However, judging from the final selection results, only less than 5 varieties have been selected by foreign companies, and more than three-quarters of the varieties have been selected by foreign companies strategically
.
The state organizes centralized drug procurement under the premise of consistency evaluation, and through the price advantage of generic drugs, promotes the realization of the replacement of the original research drug in the hospital and the further price reduction of the generic drugs
.
If in the fifth round of national procurement, the original research drug companies further maintain the strategy of gradually abandoning the original research drug market after the patent period, and shift the promotion channels of the original research drug to outside the hospital and online, it is expected that a batch of domestic pharmaceutical companies will gain more varieties of products.
Market share in the hospital
.

　　The price cuts of injections may come.

Let’s look at the situation of domestic pharmaceutical companies.
Companies such as Zhengda Tianqing, Yangtze River, Hausen, Qilu, and Kelun involve a large number of over-reviewed products
.
From the perspective of competition, the competition between rivaroxaban oral regular-release dosage forms and esomeprazole injection is fierce, with 10 or more eligible companies; from the perspective of drug treatment categories, 79 drugs cover 11 treatment categories , Digestive system and metabolic drugs, anti- tumor and immunomodulators, etc.
, among which anti-infective drugs for systemic use involve the largest number of drugs
.
In terms of dosage form, 33 of the 79 drugs are injections, and some analysis pointed out that the fifth batch of centralized procurement will be the main force of injections
.
According to Cyber ​​Blue, a total of 15 injections have been included in the four batches of national procurement that have been carried out so far.
With the advancement of centralized procurement and the acceleration of injection consistency evaluation, the number of integrated injections has increased significantly — —In the fourth round of centralized procurement, 8 injections were included, which is higher than the previous three rounds of centralized procurement
.
According to data from Mi Nei.
com, 27 of 33 injections will have terminal sales of more than 1 billion yuan in China's public medical institutions in 2019.
Once these injections are included in centralized procurement, the 600 billion injection market will usher in a new round of reshuffle
.
Some analysts pointed out that as the country organizes the drug collection to adopt more injections, the price of injections will be surging.

.
It is worth noting that due to patent issues, product characteristics and other factors, drugs that have met the conditions may not necessarily be included in the fifth batch of centralized procurement, such as sitagliptin oral regular-release dosage form, sitagliptin oral regular-release dosage form of metformin Drug patents such as sunitinib oral regular-release dosage forms may not be included before they expire
.
Recently, many provinces have issued relevant notices on the implementation of the fourth batch of national procurement
.
It is expected that the fourth batch of centralized procurement will be implemented nationwide around May .
According to the previous law of centralized procurement, after the previous batch of centralized procurement has landed, a new round of centralized procurement may begin
.

　　Attachment: Medicines that meet the requirements of the national centralized procurement (Source: Mi Nei Net Database)